DLBCL (Diffuse Large B Cell Lymphoma),Lymphoma Long-Term Benefit of Tafasitamab + Lenalidomide in DLBCL Subgroups Dec 13, 2023
DLBCL (Diffuse Large B Cell Lymphoma),Lung Cancer,Lymphoma,NSCLC (Non-Small Cell Lung Cancer) ViPOR in Relapsed/Refractory and Treatment-Naïve MCL Nov 30, 2023
DLBCL (Diffuse Large B Cell Lymphoma),Lymphoma A CRISPR-Based Anti-CD19 CAR-T (BRL-201) Shows Efficacy in R/R Non-Hodgkin’s Lymphoma Nov 29, 2023
DLBCL (Diffuse Large B Cell Lymphoma),Lymphoma Liso-Cel in Community Setting for R/R Large B-Cell Lymphoma Nov 27, 2023
DLBCL (Diffuse Large B Cell Lymphoma),Lymphoma Golidocitinib Shows Promise for Treating Refractory/Relapsed Peripheral T-Cell Lymphoma: JACKPOT8 Study Analysis Nov 20, 2023
CLL (Chronic Lymphocytic Leukemia),DLBCL (Diffuse Large B Cell Lymphoma),Leukemia,Lymphoma Rapcabtagene Autoleucel Shows Durable Efficacy And Manageable Safety In R/R DLBCL Patients Nov 08, 2023
DLBCL (Diffuse Large B Cell Lymphoma),Lymphoma,MCL (Mantle Cell Lymphoma) Pirtobrutinib Found Safe And Effective In cBTKi Pre‑Treated MCL Nov 03, 2023
DLBCL (Diffuse Large B Cell Lymphoma),Lymphoma Tafasitamab Shows Five‑Year Efficacy And Safety In R/R DLBCL Patients Nov 02, 2023
